Abstract Fibronectin expression was studied in the heart of rats given a continuous infusion of angiotensin II (Ang II). Northern nectin expression primarily within ventricular vascular tissue and the atrial endocardium. A dose-dependent reduction of fibronectin expression followed treatment with losartan, indicating an Ang II type 1 receptor-mediated effect. Normalization of blood pressure during Ang II infusion by either hydralazine or prazosin had different effects on the level of fibronectin steady-state mRNA, indicating that blood pressure elevation was not the principal factor responsible for fibronectin induction. Concurrent administration of angiotensin-converting enzyme inhibitors with Ang II attenuated the increased fibronectin expression. Our data indicate that Ang II induces an acute fibrotic response within the heart and suggests that Ang II stimulates fibronectin expression within nonmyocytic cardiac cells by a direct action. (Circ Res. 1994;74:727-739.) 
T | ahe effects of angiotensin II on the heart are diverse, and the underlying mechanisms that function in vivo have been difficult to study because of the need to dissociate indirect effects, such as blood pressure, from direct effects of the polypeptide hormone on the different cardiac cell types. Several in vivo studies have suggested that angiotensin II causes a trophic response, both on blood vessels and the heart, that is independent of hemodynamic influence.12 Car nectin expression primarily within ventricular vascular tissue and the atrial endocardium. A dose-dependent reduction of fibronectin expression followed treatment with losartan, indicating an Ang II type 1 receptor-mediated effect. Normalization of blood pressure during Ang II infusion by either hydralazine or prazosin had different effects on the level of fibronectin steady-state mRNA, indicating that blood pressure elevation was not the principal factor responsible for fibronectin induction. Concurrent administration of angiotensin-converting enzyme inhibitors with Ang II attenuated the increased fibronectin expression. Our data indicate that Ang II induces an acute fibrotic response within the heart and suggests that Ang II stimulates fibronectin expression within nonmyocytic cardiac cells by a direct action. (Circ Res. 1994; 74:727-739.) Key Words * hypertension * cardiac hypertrophyextracellular matrix * wound healing Fibronectin is a dimeric glycoprotein located in the extracellular matrix of most tissues that, through an interaction with cell surface receptors, has been shown to influence diverse cellular properties including adhesion, growth, and wound repair.9"10 Fibronectin has been identified immunohistochemically in the interstitium of cardiac tissue" and appears in the normal adult heart predominantly within small groups of myocardial cells and in connective tissue surrounding the microvasculature.12 A role for fibronectin in connecting cardiocytes to the collagen fibers and a functional influence on myocardial compliance have been suggested on the basis of these structural relations. 13 Although a functional role for fibronectin in either the normal or hypertrophic heart has not been definitively established, its importance in experimental models of wound healing has been described previously.14"15 The remodeling that occurs during the development of cardiac hypertrophy with fibrosis is considerably analogous to wound healing processes, implicating a role for fibronectin. In several previous studies, we have shown that increased fibronectin expression is associated with both vascular16 and cardiac17"18 hypertrophy. Within the heart, we have shown increased mRNA and protein levels for fibronectin after ischemia,'9 triiodothyronine treatment, and mineralocorticoid-induced hypertension.17 These levels are also increased in spontaneously hypertensive rat hearts.'8 Samuel et aP20 used in situ hybridization to show that fibronectin mRNA is associated with vascular smooth muscle cells in small coronary arteries and that, after aortic coarctation, fibronectin production is localized to focal areas of fibrosis acutely induced in this pressure-overload model. In a separate study, also using aortic coarctation, cardiac fibronectin mRNA increased within 12 hours after surgery, as measured by Northern blot analysis. 21 The present study was performed to determine the interrelation between the renin-angiotensin system, blood pressure, and fibronectin expression during cardiac fibrosis. An experimental model was used in which angiotensin II was chronically infused into rats at a pressor dose by use of osmotic minipumps. Northern and Western blot procedures were used to measure steady-state mRNA and protein content of cardiac fibronectin during the induction of a mild fibrosis. In addition, in situ hybridization was used to localize the spatial distribution of fibronectin mRNA. We found that fibronectin expression occurred most prominently in the coronary vasculature and within the atrial endocardium. Angiotensin-induced increases in fibronectin expression were associated with areas of fibrosis and were not solely dependent on blood pressure elevation. Antihypertensive drugs were given ad libitum via the drinking water, with treatment routinely initiated 1 day before pump implant. The dosages used were as follows: hydralazine, 2 mg/kg per day; prazosin, 0.5 mg/kg per day; losartan, 1 or 10 mg/kg per day; and trandolapril, 0.5 mg/kg per day. Systolic blood pressures were obtained by tail-cuff plethysmography. Blood pressure levels were determined before drug treatment, 1 day after implant, and 4 to 6 hours before killing. In all experiments, the reported value at each time point is an average of multiple (four to six) recordings. Nembutal was used as surgical anesthesia (50 mg/kg) and for overdosing (0.5 g/kg) the rats. Cardiectomy was followed by retrograde aortic perfusion with phosphate-buffered saline (PBS) containing 4% (wt/vol) paraformaldehyde before histochemical analysis. For biochemical analysis, hearts were dissected by removal of the pericardium. Ventricle free walls, septum, and atria were separated from fibrous septum and then washed in cold PBS.
Materials and Methods

Drugs
Samples were flash-frozen in liquid N2 for subsequent extraction of RNA or protein.
RNA Isolation and Northern Blot Hybridization
Total RNA from cardiac tissue was extracted by the method of Chomczynski and Sacchi22 with a 20-fold volume of guanidinium thiocynate buffer for the initial homogenization. Northern blot analysis was performed as described by Mamuya and Brecher.) cDNA probes were generated using a randomprime nucleotide synthesis kit (Amersham International, UK), and hybridization was performed at 55°C for atrial natriuretic factor (ANF) and at 62°C for all other cDNA probes.
Tissue Preparation and In Situ Hybridization
Fixation of tissue for in situ hybridization, autoradiography, or staining followed procedures described by Wilkinson et al.23 Briefly, perfused hearts were cut transversely at three parallel locations, vacuum-fixed for 16 to 24 hours in PBS containing 4% paraformaldehyde at 4°C, and then washed, dehydrated, and embedded in Paraplast (Oxford Laboratories, St Louis, Mo). Serial sections (4 to 6 ,um) were transferred to gelatincoated slides for in situ hybridization. Staining with hematoxylin and eosin or Masson's trichrome followed standardized protocols. In situ hybridization was performed essentially as described by Sassoon et icant growth of the heart, as indexed by both heart weight and the heart weight-to-body weight ratio, was seen after 3 days of treatment with either dosage. If treatment was continued with a pressor dose of angiotensin II, the difference in the weight of treated hearts compared with age-matched control hearts increased. When animals were treated with angiotensin II for 3 days and then withdrawn from treatment for a 1-week postinfusion period, blood pressure became hypertensive and subsequently returned to normotensive levels. Coincident with this was a regression of hypertrophic indexes to values no different from control for both heart weight and heart weight-to-body weight ratios.
Northern blot analysis was performed on left ventricular RNA taken from animals treated with pressor (0.75 mg/kg per day) and subpressor (0.30 mg/kg per day) doses of angiotensin II for 3 days (Fig 1A) . Steady-state mRNA levels for fibronectin were increased between 10-and 20-fold after treatment with the higher dose. No increase in fibronectin expression was found in the left ventricle from animals treated with the subpressor level of angiotensin II. In contrast to the left ventricle, steady-state mRNA levels for fibronectin did not change in left atrial tissue taken from animals treated with a pressor dose of angiotensin II for 3 days (Fig iB) . The changes occurring in the left ventricle in response to angiotensin II infusion for 3 days at a pressor dose also were found in the right ventricle and were quantitatively comparable (data not shown). Further analysis was performed on left ventricular RNA taken from animals treated with angiotensin II (125 ng/min) for 1 day or 3 days or for 3 days followed by a 7-day recovery period without treatment (Fig 1C) . Steady-state mRNA levels for fibronectin were increased more than fivefold after A Western blot measuring immunodetectable fibronectin in ventricular extracts is shown in Fig 3A. A major band was identified corresponding to -220 kD, which consistently migrated faster than plasma fibronectin (not shown) and indicated extractable cellular fibronectin. Increased protein was obvious after 3 days of treatment, the average increase being 1.67+0.1-fold for six separate animals (Fig 3B) . This increase in immunodetectable fibronectin during the 7-day period indicated a dissociation between fibronectin mRNA and protein between days 3 and 7. Of particular interest was the ventricular fibronectin content after the recovery period, during which the levels were significantly below the values for animals treated for 3 days. Thus, angiotensin II treatment induced reversible changes in fibronectin expression at the level of both mRNA and protein.
In situ hybridization was used to study the localization of fibronectin mRNA within the rat heart. Histological analysis of control and angiotensin Il-treated ventricular tissue (Fig 4A and 4C) indicated that, after 3 days of infusion with angiotensin II, there was a mild to moderate fibrosis. The regions of fibrosis were often interstitial, but perivascular fibrosis also was obvious. The fibrotic regions were focal and were distributed both in left and right ventricular tissue with no obvious selective distribution either in endocardial or myocardial regions. In the control ventricle, in situ hybridization indicated fibronectin mRNA almost exclusively associated with small arteries, with the vascular smooth muscle cells as the major source (Fig 4B) . After 3 days of angiotensin II infusion, in situ analysis showed a strong signal for fibronectin mRNA associated with interstitial fibroblasts primarily in the regions of fibrosis (Fig 4D) , and no significant signal appeared within In a separate series of experiments (data not shown) in which [3H]thymidine was injected into rats treated with angiotensin II for up to 3 days, the thymidine label was found almost exclusively in nuclei of interstitial and perivascular fibroblasts within fibrotic regions. Occasional label was associated with interstitial fibroblasts outside these areas of fibrosis and within mesothelial cells. Of note was the virtual absence of label within other cell types of the heart, including myocytes and vascular smooth muscle cells. Thus, the interstitial fibroblasts appeared to be the principal cell type induced to proliferate or enter S phase after hormone administration. With in situ hybridization, we found no detectable fibronectin mRNA in cell types other than vascular smooth muscle cells and proliferating interstitial fibroblasts in either control or angiotensin IItreated animals. Although we cannot rule out the possibility that myocytes do express low levels of fibronectin, it would appear that the increased steady-state fibronectin mRNA levels detected by Northern blot analysis correspond in large part to the interstitial fibroblasts associated with fibrosis, consistent with the recent findings of Samuel et al,20 who observed fibronectin that was associated with fibrotic regions induced by acute pressure overload after aortic coarctation.
In situ hybridization of atrial tissue from untreated or treated rats showed fibronectin mRNA associated with the connective tissue component of the endocardium. A trichrome stain of atria (Fig 5A) showed the extracellular matrix associated with both endocardium and epicardium. A comparison of serial sections stained either with hematoxylin and eosin (Fig 5B) or analyzed by in situ hybridization for fibronectin (Fig 5C) showed dense accumulation of silver grains primarily in the endocardial regions. The intensity of the signal within the endocardial region was considerably greater than that associated with the vascular smooth muscle cells within the atria, suggesting that the relatively high amount of steady-state fibronectin mRNA within the atria was due primarily to connective tissue cells within the endocardium. Angiotensin II infusion produced no obvious qualitative or quantitative change in atrial expression of fibronectin by in situ hybridization or histological evidence of fibrosis (data not shown), consistent with Northern blot analysis shown in Fig 1B. To distinguish the role of angiotensin II in fibronectin regulation from the effect of blood pressure elevation, antihypertensive drugs were given during angiotensin II infusion. The effects of antihypertensive drugs on Wistar rats treated with pressor doses of angiotensin II are summarized in Table 2 . Coadministration of either 5 mg/kg per day of the vasodilator hydralazine, 0.2 mg/kg per day of the a1-adrenergic receptor antagonist agonist prazosin, or 10 mg/kg per day of angiotensin II type 1 (AT1) receptor antagonist losartan was effective in normalizing blood pressure. However, only the highdose losartan was shown to completely block the increase in heart weight after 3 days of angiotensin administration. A lower dose of losartan, 1 mg/kg per day, did not return systolic pressure to normal, although this dose of losartan did significantly reduce heart weight gain.
The effect of losartan on fibronectin mRNA expression during angiotensin infusion is summarized in Fig 6. A dose-dependent attenuation of fibronectin expression was found 3 days after coadministration of losartan with angiotensin II. At 10 mg/kg per day, losartan blocked the increase in systolic blood pressure (132±4 mm Hg) expected after angiotensin II infusion and completely eliminated the increase in fibronectin expression. By use of 1 mg/kg per day of losartan, an intermediate level of blood pressure control was achieved (158±5 mm Hg) in animals given angiotensin II. In the left ventricle from these animals, increases in fibronectin expression were at a level between control and angiotensin II-treated animals. Changes comparable to those shown for fibronectin mRNA were found when mRNA for collagen types I and IV was analyzed in the ventricles of losartan-treated rats (data not shown).
Both hydralazine and prazosin administered during angiotensin II treatment lowered blood pressure significantly below hypertensive levels. Fig 7 shows a representative Northern blot of left ventricles from rats treated with angiotensin II for 3 days along with either hydralazine or prazosin. The steady-state level of fibronectin mRNA in ventricles from animals receiving hydralazine during angiotensin II treatment was no different from control animals after the third day of infusion. In contrast, animals whose blood pressures were normalized by prazosin during angiotensin II treatment had left ventricular fibronectin levels typical of rats made hypertensive after 3 days of angiotensin II. Changes in collagen type I mRNA reflected the changes seen with fibronectin. Taken together, these data indicate that elevated blood pressure is not the principal regulator of fibronectin induction in the left ventricle. In addition, it suggests that pharmacologic intervention may influence the mechanism responsible for regulating fibronectin expression.
To examine the potential influence of converting enzyme inhibitors on angiotensin II-mediated fibronectin induction, trandolapril was administered during angiotensin II treatment. Fig 8 shows a reduced steady-state mRNA level of fibronectin in ventricular tissue from rats treated with angiotensin II plus trandolapril when compared with tissue from rats treated with angiotensin II alone. This effect appeared to be specific for fibronectin among the genes examined under these conditions. Unlike fibronectin, neither collagen type I, collagen type IV, nor ANF expression was changed by trandolapril. Trandolapril treatment did not lower blood pressure in angiotensin Il-treated rats (204± 10 mm Hg); thus, the suppressive effect on fibronectin mRNA was independent of any change in blood pressure. tP<.05 vs 3-day Ang {I-treated rats.
Discussion
A role for the renin-angiotensin system in the development of hypertension-induced cardiac hypertrophy has long been suspected, yet it has been difficult to establish whether a causative role for angiotensin II in cardiac hypertrophy is due to direct or indirect effects of the hormone. In the present study, we subcutaneously administered angiotensin II to adult rats to study the interrelations between this hormone, cardiac fibronectin expression, and the cellular changes associated with hypertrophy. Our results support the interpretation that fibronectin expression in nonmyocytic cells of the ventricular myocardium undergoes an increase in response to pressors levels of angiotensin II. This increase apparently leads to an accumulation of fibronectin associated with elevated collagen expression, fibrosis, and myocyte hypertrophy. In addition, we suggest that angiotensin II may be acting directly on cardiac fibroblasts and that
Cbl pharmacologic intervention may modify this process via a mechanism distinct from blood pressure reduction.
The transient increase in fibronectin steady-state mRNA in ventricular tissue during a 7-day angiotensin II administration period contrasted with the progressive accumulation of immunoreactive fibronectin. This dissociation between cardiac fibronectin mRNA and protein was also documented in the rat after induction of cardiac hypertrophy by triiodothyronine administration. '7 In that study, mRNA levels rose and fell over a 10-day treatment period, with maximum induction between 3 and 6 days, whereas immunoreactive protein was severalfold more abundant after 10 days. was induced by aortic coarctation, and a similar transient increase was found in fibronectin mRNA 1 to 3 days after surgery, followed by a progressive reduction to control levels during the subsequent 10 days. Although fibronectin itself was not determined in those studies, Northern blot analysis showed that induction of fibronectin mRNA preceded that for fibrillar collagen types, consistent with the findings in the present study.
In a study by Chapman et al,33 a pressure-overload model involving constriction both of aorta and right renal artery was used to study collagen gene expression in the rat heart. It was found that a transient increase in collagen types I and III occurred 3 days after surgery and returned to control levels after 7 days. These changes were identified as being produced in cardiac fibroblasts, and distinctions between regulatory events occurring in myocytes and fibroblasts were made during the hypertrophic response in this model. We found elevated ventricular levels of both fibronectin mRNA and protein by the third day of angiotensin II infusion. Increase in collagen type I also occurred but was not induced as rapidly. These increases were consistently found within cardiac tissue undergoing hypertrophy and a mild interstitial fibrosis. Increased fibronectin expression followed by collagen deposition and fiber formation is a major feature of wound healing in diverse tissue types. It is thought that fibronectin, through interactions with specific binding domains, may influence the organization of collagen bundles as healing progresses. 34, 35 In normal wound healing, during the formation of evolving granulation tissue, collagen deposits remain to form fibrils, whereas fibronectin slowly resolves from the wound area.36,37 In contrast, keloid lesions, which are characterized by abnormal collagen metabolism and scar formation, contain fibroblasts that maintain a fourfold increase in fibronectin biosynthesis corresponding to an increased level of fibronectin mRNA. 38 In the present study, we report a potentially reversible accumulation of fibronectin within the ventricle undergoing fibrosis, which appears to depend on the presence of angiotensin II. The loss of immunoreactive fibronectin after cessation of treatment with angiotensin II could reflect increased degradation of the protein, perhaps by the action of specific proteases induced by growth factors or by other posttranscriptional mechanisms.
In two previous studies of the rat heart after acute cardiac injury due to either ischemia or acute pressure overload, increases in fibrillar collagen types I and III were preceded by fibronectin accumulation,'719 a temporal relation we found in response to angiotensin II. In the failing human heart, fibronectin was colocalized with collagen types I, III, and IV, and a positive correlation was established between increased fibronectin and other extracellular matrix proteins by electron microscopy and immunofluorescence.39 Moreover, in the spontaneously hypertensive rat, which exhibits cardiac hypertrophy with associated fibrosis,41' the normal decrease in cardiac fibronectin seen with aging does not occur, implying increased fibronectin production.18 Specifically how fibronectin accumulation influences collagen deposition and extracellular matrix structure during the abnormal fibrous tissue response found in the heart of hypertensive animals has not been clearly established.
Fibrosis occurred rapidly after angiotensin II administration and appeared to be responsible for the increased expression of fibronectin mRNA measured by Northern blot analysis. In situ hybridization showed that the major difference between treated and control animals was the fibronectin mRNA associated with proliferating interstitial fibroblasts, particularly in perivascular regions. These findings are consistent with those recently reported by Samuel et a120 showing fibronectin expression associated with the fibrosis induced by aortic coarctation. In those studies, the fibrosis also occurred rapidly and was attributed to acute pressure overload because of the predominant response in the left ventricle.
Tan et a15 used a subpressor angiotensin infusion model to produce cardiac fibrosis. In those studies, evidence for fibrosis was found after 1 day of treatment, and most of the cellular proliferation occurred within a 2-day period, subsequently declining to control levels. These findings were correlated with myocytolysis and were induced in a normotensive animal model. Our experimental model differed from that of Tan et al mainly in the dose and route of administration of the angiotensin II. Subcutaneous (0.75 mg/kg per day) rather than intraperitoneal (0.96 to 1.44 mg/kg per day) minipump implantation resulted in a more effective pressor response despite the lower dose. Histological analysis in the present study showed the fibrosis to be obvious even after only 1 day of treatment with this lower dose, yet the fibrotic regions remained sparsely dispersed throughout the ventricles and did not appear to progress or worsen after the third day. Autoradiographic analysis of thymidine incorporation also was consistent with a rapid response that did not progressively increase during the initial 3 days of treatment. Despite the differences in protocols, the similar findings with respect to fibrosis in animals given both pressor or subpressor doses does suggest a direct effect of angiotensin II on cardiac cells.
The presence of angiotensin receptors throughout the rat heart has been described, 41 Several in vitro studies also suggest that angiotensin II mediates both stimulation of 3T3 cell division62 and increases cardiac fibroblast expression of fibronectin and collagen63 through the AT1 receptor. In addition, studies by Baker and Aceto6 have shown direct effects of angiotensin II on cardiac myocytes and have suggested that local production of transforming growth factor-p1 (TGF-p1) may precede and perhaps cause the increase in fibronectin expression. TGF-,3 has been shown to be an important regulator of extracellular matrix proteins, including fibronectin, in diverse cell types,64-66 and recent speculation67 concerning the potential role of TGF-,8 in self-limiting fibrotic processes suggests a role for this growth factor in cardiac fibrosis. Villarreal and Dillmann21 recently showed that steady-state mRNA levels for TGF-p81, but not TGF-83, in the heart increased very rapidly (within 12 hours) after thoracic banding and remained elevated for 2 weeks. This rapid increase preceded increases in both fibronectin and collagen mRNA, suggesting a functional role for this growth factor in the development of hypertrophy. Which growth factors specifically modulate the progression and regression of the hypertrophic response remains an important question in the understanding of cardiac biology. Our data suggest that angiotensin II has a role in promoting the expression of fibronectin during the remodeling of the ventricle. How these alterations in ventricular fibronectin functionally affect ventricular performance is unknown at present. However, if indeed using cardiac cell explants, which suggest that both pharmacologic intervention modifies the response of nonmyocytic cells to angiotensin II, this in vivo model can provide an approach in the study of intercellular signaling mechanisms that regulate ventricular remodeling in situ.
